Marina L. Sehman, RPh, PharmD

HIV is of interest among many in managed care. This paper focuses on the costs and demographic characteristics associated with new HIV therapy initiators.

New and forthcoming oral anticoagulants, which do not require prothrombin time monitoring, will offer patients and providers additional therapeutic options.

Incivek and Victrelis, approved for Hepatitis C within weeks of each other in May 2011, look to change the way the disease is treated.

Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.